Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Utilization of follow-up specimens from viremic blood donors to assess the value of west nile virus immunoglobulin G avidity as an indicator of recent infection.

Literature DB >> 16148183

Utilization of follow-up specimens from viremic blood donors to assess the value of west nile virus immunoglobulin G avidity as an indicator of recent infection.

Harry E Prince¹, Mary Lapé-Nixon, Michael P Busch, Leslie H Tobler, Gregory A Foster, Susan L Stramer.

Abstract

The value of West Nile virus immunoglobulin G avidity for distinguishing recent from past infection was investigated using 348 follow-up specimens from 170 viremic blood donors. Low avidity accurately indicated infection within the previous 4 months. However, due to rapid avidity maturation in some individuals, high avidity did not accurately indicate past infection.

Entities: Disease Species

Mesh：

Substances：

Year: 2005 PMID： 16148183 PMCID： PMC1235801 DOI： 10.1128/CDLI.12.9.1123-1126.2005

Source DB: PubMed Journal: Clin Diagn Lab Immunol ISSN： 1071-412X

14 in total

1. Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

Authors: Harry E Prince; Amy L Leber
Journal: Clin Diagn Lab Immunol Date: 2002-07

2. Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

Authors: Vanda Akico Ueda Fick de Souza; Silvana Fernandes; Evaldo Stanislau Araújo; Adriana Fumie Tateno; Olímpia M N P F Oliveira; Renato Reis Oliveira; Cláudio Sérgio Pannuti
Journal: J Clin Microbiol Date: 2004-04 Impact factor: 5.948

3. Maturation of rubella IgG avidity over time after acute rubella infection.

Authors: B Böttiger; I P Jensen
Journal: Clin Diagn Virol Date: 1997-08

4. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors.

Authors: Harry E Prince; Leslie H Tobler; Mary Lapé-Nixon; Gregory A Foster; Susan L Stramer; Michael P Busch
Journal: J Clin Microbiol Date: 2005-09 Impact factor: 5.948

5. Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: analysis of 2003 data to inform 2004 decision making.

Authors: Brian Custer; Peter A Tomasulo; Edward L Murphy; Sally Caglioti; Dennis Harpool; Patrick McEvoy; Michael P Busch
Journal: Transfusion Date: 2004-11 Impact factor: 3.157

6. Update: West Nile virus screening of blood donations and transfusion-associated transmission--United States, 2003.

Authors:
Journal: MMWR Morb Mortal Wkly Rep Date: 2004-04-09 Impact factor: 17.586

7. Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies.

Authors: Wayne R Hogrefe; Ronald Moore; Mary Lape-Nixon; Michael Wagner; Harry E Prince
Journal: J Clin Microbiol Date: 2004-10 Impact factor: 5.948

Utilization of follow-up specimens from viremic blood donors to assess the value of west nile virus immunoglobulin G avidity as an indicator of recent infection.

1. Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

2. Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

3. Maturation of rubella IgG avidity over time after acute rubella infection.

4. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors.

5. Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: analysis of 2003 data to inform 2004 decision making.

6. Update: West Nile virus screening of blood donations and transfusion-associated transmission--United States, 2003.

7. Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies.

8. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection.

9. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.

10. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases.

1. A brief report of West Nile Virus neuroinvasive disease in the summer of 2012 in Hamilton, Ontario.

2. West Nile virus IgM and IgG antibodies three years post- infection.